Werewolf Therapeutics (HOWL) shares have more than doubled in value following the announcement of a definitive agreement to merge with privately held Ambros Therapeutics.

Merger Details

Once the transaction is completed, HOWL shareholders will retain approximately 6.8% ownership of the joint company, as revealed in a press release by Werewolf Therapeutics on August 21.

The agreement brings together Werewolf’s expertise in developing innovative therapeutics with Ambros’s late-stage neridronate program, which is being developed as a treatment for Complex Regional Pain Syndrome Type 1 (CRPS-1).

Ambros began its pivotal CRPS-RISE Phase 3 clinical trial in June, and neridronate has previously received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations.

Why Investors Are Excited

The merger has generated significant excitement among investors due to the potential of neridronate to become the first FDA-approved therapy for CRPS-1, a market with an estimated 65,000 newly diagnosed patients in the U.S. annually and no currently approved treatment.

The combined entity will focus on neridronate, with CRPS-RISE Phase 3 results expected in 2028. If the trial succeeds, the asset could potentially become a groundbreaking treatment for CRPS-1.

Moreover, the deal brings substantial funding, with investors committing $150 million through an oversubscribed PIPE. The combined entity is expected to be funded through the CRPS-RISE Phase 3 results and planned New Drug Application (NDA) submission.

Wall Street’s View on Werewolf Therapeutics

Heading into August 21, Wall Street had a consensus ‘Moderate Buy’ rating on HOWL shares, with a mean price target of approximately $6.

This means that experts viewed Werewolf Therapeutics as notably undervalued, even as a standalone company.

What’s Next for HOWL Shares?

While the explosive surge has already baked in the merger optimism, there is still a major catalyst pipeline ahead. The combined company will focus on neridronate, with CRPS-RISE Phase 3 results expected in 2028.

However, investors should not overlook the substantial dilution embedded in the transaction. Existing Werewolf shareholders are expected to own only approximately 6.8% of the combined company, while Ambros holders receive 71.7% and PIPE investors 21.5%.

In short, further upside is possible, but the next leg higher will depend on neridronate’s progress rather than the merger announcement itself.